title: Metabolic syndrome - the consequence of lifelong treatment of bipolar affective disorder.
abstract: Mood disturbances are characteristic and dominant feature of Mood disorders. Bipolar Affective Disorder (BAD) is a mood disorder which occurs equally in both sexes. BAD may occur in co morbidity with other mental diseases and disorders such as: Anorexia Nervosa, Bulimia Nervosa, Attention Deficit, Panic Disorder and Social Phobia. However, medical disorders (one or more) can also coexist with BAD. Metabolic syndrome is a combination of metabolic disorders that increase the risk of developing cardiovascular disease. A 61-year old female patient has been receiving continuous and systematic psychiatric treatment for Bipolar Affective Disorder for the last 39 years. The first episode was a depressive one and it occurred after a child delivery. Seventeen years ago the patient developed diabetes (diabetes type II), and twelve years ago arterial hypertension was diagnosed. High cholesterol and triglyceride levels as well as weight gain were objective findings. During the last nine years she has been treated for lower leg ulcer. Since metabolic syndrome includes abdominal obesity, hypertension, diabetes mellitus, increased cholesterol and serum triglyceride levels, the aforesaid patient can be diagnosed with Metabolic Syndrome. When treating Bipolar Affective Disorder, the antipsychotic drug choice should be careful and aware of its side-effects in order to avoid the development or aggravation of metabolic syndrome.
authors.affiliation: Community Primary Health Centre, Primorsko-goranska county, 51000 Rijeka, Croatia. elizabeta.dadic.hero@ri.t-com.hr
authors.forename: Elizabeta
authors.initials: E
authors.lastname: Dadić-Hero
authors.forename: Klementina
authors.initials: K
authors.lastname: Ruzić
authors.forename: Tanja
authors.initials: T
authors.lastname: Grahovac
authors.forename: Duska
authors.initials: D
authors.lastname: Petranović
authors.forename: Mirjana
authors.initials: M
authors.lastname: Graovac
authors.forename: Tija Zarković
authors.initials: TZ
authors.lastname: Palijan
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D001786:Blood Glucose / Q000378:metabolism; D003131:Combined Modality Therapy; D015897:Comorbidity; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008019:Life Style; D008134:Long-Term Care; D024821:Metabolic Syndrome / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D008875:Middle Aged; D010359:Patient Readmission
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose